# Trupanion, Inc.: financial statements, quarterly

TRUP · Nasdaq · CIK 1371285 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/trup.md) · [Financials](/companies/trup/financials.md) · [Filings](/companies/trup/filings.md) · [Insiders](/companies/trup/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/trup/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [286](/filings/0001371285-24-000282.md) | [296 d](/filings/0001371285-26-000018.md) | [306](/filings/0001371285-25-000119.md) | [315](/filings/0001371285-25-000187.md) | [327](/filings/0001371285-25-000250.md) | [337 d](/filings/0001371285-26-000018.md) | [342](/filings/0001371285-26-000096.md) | [354](/filings/0001371285-26-000172.md) | [367](/filings/0001371285-25-000250.md) | [377 d](/filings/0001371285-26-000018.md) | [384](/filings/0001371285-26-000096.md) | [393](/filings/0001371285-26-000172.md) |
| Cost of revenue | $m | [251](/filings/0001371285-24-000282.md) | [256 d](/filings/0001371285-26-000018.md) | [270](/filings/0001371285-25-000119.md) | [275](/filings/0001371285-25-000187.md) | [278](/filings/0001371285-25-000250.md) | [284 d](/filings/0001371285-26-000018.md) | [291](/filings/0001371285-26-000096.md) | [299](/filings/0001371285-26-000172.md) | [307](/filings/0001371285-25-000250.md) | [312 d](/filings/0001371285-26-000018.md) | [323](/filings/0001371285-26-000096.md) | [328](/filings/0001371285-26-000172.md) |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(3.5)](/filings/0001371285-24-000282.md) | [0.4 d](/filings/0001371285-26-000018.md) | [(6.1)](/filings/0001371285-25-000119.md) | [(5.5)](/filings/0001371285-25-000187.md) | [1.7](/filings/0001371285-25-000250.md) | [0.3 d](/filings/0001371285-26-000018.md) | [(1.5)](/filings/0001371285-26-000096.md) | [2.3](/filings/0001371285-26-000172.md) | [5.9](/filings/0001371285-25-000250.md) | [7.1 d](/filings/0001371285-26-000018.md) | [4.8](/filings/0001371285-26-000096.md) | [6.4](/filings/0001371285-26-000172.md) |
| Interest expense | $m | [3.1](/filings/0001371285-24-000282.md) | [3.7 d](/filings/0001371285-26-000018.md) | [3.6](/filings/0001371285-25-000119.md) | [3.7](/filings/0001371285-25-000187.md) | [3.8](/filings/0001371285-25-000250.md) | [3.4 d](/filings/0001371285-26-000018.md) | [3.2](/filings/0001371285-26-000096.md) | [3.7](/filings/0001371285-26-000172.md) | [2.8](/filings/0001371285-25-000250.md) | [4.1 d](/filings/0001371285-26-000018.md) | [1.9](/filings/0001371285-26-000096.md) | [1.8](/filings/0001371285-26-000172.md) |
| Income tax | $m | [(0.0)](/filings/0001371285-24-000282.md) | [0.1 d](/filings/0001371285-26-000018.md) | [(0.0)](/filings/0001371285-25-000119.md) | [(0.0)](/filings/0001371285-25-000187.md) | [0.0](/filings/0001371285-25-000250.md) | [0.0 d](/filings/0001371285-26-000018.md) | [0.0](/filings/0001371285-26-000096.md) | [1.1](/filings/0001371285-26-000172.md) | [0.7](/filings/0001371285-25-000250.md) | [0.7 d](/filings/0001371285-26-000018.md) | [1.1](/filings/0001371285-26-000096.md) | [0.5](/filings/0001371285-26-000172.md) |
| Net income | $m | [(4.0)](/filings/0001371285-24-000282.md) | [(2.2) d](/filings/0001371285-26-000018.md) | [(6.9)](/filings/0001371285-25-000119.md) | [(5.9)](/filings/0001371285-25-000187.md) | [1.4](/filings/0001371285-25-000250.md) | [1.7 d](/filings/0001371285-26-000018.md) | [(1.5)](/filings/0001371285-26-000096.md) | [9.4](/filings/0001371285-26-000172.md) | [5.9](/filings/0001371285-25-000250.md) | [5.6 d](/filings/0001371285-26-000018.md) | [4.9](/filings/0001371285-26-000096.md) | [6.8](/filings/0001371285-26-000172.md) |
| Diluted EPS | $ per share | [(0.10)](/filings/0001371285-24-000282.md) | not reported | [(0.16)](/filings/0001371285-25-000119.md) | [(0.14)](/filings/0001371285-25-000187.md) | [0.03](/filings/0001371285-25-000250.md) | not reported | [(0.03)](/filings/0001371285-26-000096.md) | [0.22](/filings/0001371285-26-000172.md) | [0.13](/filings/0001371285-25-000250.md) | not reported | [0.11](/filings/0001371285-26-000096.md) | [0.16](/filings/0001371285-26-000172.md) |
| Basic EPS | $ per share | [(0.10)](/filings/0001371285-24-000282.md) | not reported | [(0.16)](/filings/0001371285-25-000119.md) | [(0.14)](/filings/0001371285-25-000187.md) | [0.03](/filings/0001371285-25-000250.md) | not reported | [(0.03)](/filings/0001371285-26-000096.md) | [0.22](/filings/0001371285-26-000172.md) | [0.14](/filings/0001371285-25-000250.md) | not reported | [0.11](/filings/0001371285-26-000096.md) | [0.16](/filings/0001371285-26-000172.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: not reported
- Research and development: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [150](/filings/0001371285-23-000302.md) | [148](/filings/0001371285-25-000052.md) | [146](/filings/0001371285-24-000120.md) | [124](/filings/0001371285-24-000210.md) | [137](/filings/0001371285-24-000282.md) | [160](/filings/0001371285-26-000018.md) | [166](/filings/0001371285-25-000119.md) | [123](/filings/0001371285-25-000187.md) | [155](/filings/0001371285-25-000250.md) | [138](/filings/0001371285-26-000172.md) | [153](/filings/0001371285-26-000096.md) | [149](/filings/0001371285-26-000172.md) |
| Current assets | $m | [561](/filings/0001371285-23-000302.md) | [562](/filings/0001371285-25-000052.md) | [571](/filings/0001371285-24-000120.md) | [579](/filings/0001371285-24-000210.md) | [600](/filings/0001371285-24-000282.md) | [597](/filings/0001371285-26-000018.md) | [628](/filings/0001371285-25-000119.md) | [629](/filings/0001371285-25-000187.md) | [668](/filings/0001371285-25-000250.md) | [691](/filings/0001371285-26-000172.md) | [705](/filings/0001371285-26-000096.md) | [719](/filings/0001371285-26-000172.md) |
| Total assets | $m | [772](/filings/0001371285-23-000302.md) | [783](/filings/0001371285-25-000052.md) | [789](/filings/0001371285-24-000120.md) | [796](/filings/0001371285-24-000210.md) | [816](/filings/0001371285-24-000282.md) | [807](/filings/0001371285-26-000018.md) | [837](/filings/0001371285-25-000119.md) | [848](/filings/0001371285-25-000187.md) | [880](/filings/0001371285-25-000250.md) | [915](/filings/0001371285-26-000172.md) | [922](/filings/0001371285-26-000096.md) | [931](/filings/0001371285-26-000172.md) |
| Current liabilities | $m | [348](/filings/0001371285-23-000302.md) | [344](/filings/0001371285-25-000052.md) | [352](/filings/0001371285-24-000120.md) | [356](/filings/0001371285-24-000210.md) | [362](/filings/0001371285-24-000282.md) | [350](/filings/0001371285-26-000018.md) | [369](/filings/0001371285-25-000119.md) | [372](/filings/0001371285-25-000187.md) | [391](/filings/0001371285-25-000250.md) | [410](/filings/0001371285-26-000172.md) | [408](/filings/0001371285-26-000096.md) | [405](/filings/0001371285-26-000172.md) |
| Total liabilities | $m | [483](/filings/0001371285-23-000302.md) | [479](/filings/0001371285-25-000052.md) | [486](/filings/0001371285-24-000120.md) | [490](/filings/0001371285-24-000210.md) | [496](/filings/0001371285-24-000282.md) | [484](/filings/0001371285-26-000018.md) | [503](/filings/0001371285-25-000119.md) | [492](/filings/0001371285-25-000187.md) | [512](/filings/0001371285-25-000250.md) | [531](/filings/0001371285-26-000172.md) | [527](/filings/0001371285-26-000096.md) | [521](/filings/0001371285-26-000172.md) |
| Long-term debt | $m | [128](/filings/0001371285-23-000302.md) | [128](/filings/0001371285-24-000282.md) | [127](/filings/0001371285-24-000120.md) | [128](/filings/0001371285-24-000210.md) | [128](/filings/0001371285-24-000282.md) | [128](/filings/0001371285-25-000250.md) | [128](/filings/0001371285-25-000119.md) | [113](/filings/0001371285-25-000187.md) | [114](/filings/0001371285-25-000250.md) | [102](/filings/0001371285-26-000172.md) | [99.3](/filings/0001371285-26-000096.md) | [96.9](/filings/0001371285-26-000172.md) |
| Current portion of debt | $m | [1.4](/filings/0001371285-23-000302.md) | [1.4](/filings/0001371285-25-000052.md) | [1.4](/filings/0001371285-24-000120.md) | [1.4](/filings/0001371285-24-000210.md) | [1.4](/filings/0001371285-24-000282.md) | [1.4](/filings/0001371285-26-000018.md) | [1.4](/filings/0001371285-25-000119.md) | [1.4](/filings/0001371285-25-000187.md) | [0.8](/filings/0001371285-25-000250.md) | [10.0](/filings/0001371285-26-000172.md) | [10.0](/filings/0001371285-26-000096.md) | [10.0](/filings/0001371285-26-000172.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [289](/filings/0001371285-24-000282.md) | [304](/filings/0001371285-26-000018.md) | [303](/filings/0001371285-25-000187.md) | [306](/filings/0001371285-25-000250.md) | [320](/filings/0001371285-25-000250.md) | [323](/filings/0001371285-26-000172.md) | [334](/filings/0001371285-26-000172.md) | [355](/filings/0001371285-26-000172.md) | [369](/filings/0001371285-25-000250.md) | [384](/filings/0001371285-26-000172.md) | [395](/filings/0001371285-26-000172.md) | [410](/filings/0001371285-26-000172.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [11.4 d](/filings/0001371285-24-000282.md) | [17.5 d](/filings/0001371285-26-000018.md) | [2.4](/filings/0001371285-25-000119.md) | [6.9 d](/filings/0001371285-25-000187.md) | [15.3 d](/filings/0001371285-25-000250.md) | [23.7 d](/filings/0001371285-26-000018.md) | [16.0](/filings/0001371285-26-000096.md) | [15.0 d](/filings/0001371285-26-000172.md) | [29.2 d](/filings/0001371285-25-000250.md) | [29.3 d](/filings/0001371285-26-000018.md) | [14.6](/filings/0001371285-26-000096.md) | [21.0 d](/filings/0001371285-26-000172.md) |
| Capital expenditure | $m | [4.4 d](/filings/0001371285-24-000282.md) | [4.0 d](/filings/0001371285-26-000018.md) | [3.1](/filings/0001371285-25-000119.md) | [2.9 d](/filings/0001371285-25-000187.md) | [1.9 d](/filings/0001371285-25-000250.md) | [1.9 d](/filings/0001371285-26-000018.md) | [1.9](/filings/0001371285-26-000096.md) | [3.0 d](/filings/0001371285-26-000172.md) | [5.3 d](/filings/0001371285-25-000250.md) | [3.9 d](/filings/0001371285-26-000018.md) | [0.8](/filings/0001371285-26-000096.md) | [1.8 d](/filings/0001371285-26-000172.md) |
| Share repurchases | $m | [0.0 d](/filings/0001371285-23-000302.md) | [0.0 d](/filings/0001371285-25-000052.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [40.8](/filings/0001371285-23-000302.md) | [41.1](/filings/0001371285-24-000120.md) | [41.4](/filings/0001371285-24-000210.md) | [41.5](/filings/0001371285-24-000282.md) | [41.9](/filings/0001371285-25-000119.md) | [42.1](/filings/0001371285-25-000187.md) | [42.8](/filings/0001371285-25-000250.md) | [42.8](/filings/0001371285-26-000096.md) | [43.3](/filings/0001371285-26-000172.md) | [43.6](/filings/0001371285-25-000250.md) | [43.7](/filings/0001371285-26-000096.md) | [43.8](/filings/0001371285-26-000172.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 43,872,611 at 2026-07-29, from the cover of the [10-Q filed 2026-08-05](/filings/0001371285-26-000172.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.